β受体阻滞剂与SSRI联用的不良事件范围综述
该范围综述检索1990年至2025年英文文献,纳入48篇文章,评估β受体阻滞剂与选择性5-羟色胺再摄取抑制剂(SSRI)联用的不良事件。最常见报告为心动过缓,血压变化见于半数探索该结局的研究,神经认知症状异质,另有自伤相关病例报告。作者提出这些信号多与CYP2D6药代动力学相互作用有关,需在稳健观察性研究中验证。
要点
- β受体阻滞剂与SSRI联用最常见不良事件为心动过缓,多与美托洛尔或普萘洛尔相关。
- 血压变化(含低血压)在探索该结局的研究中约半数被观察到。
- postulated机制主要为CYP2D6介导的药代动力学相互作用。
核心结论
- β受体阻滞剂与SSRI联用的不良事件报告可能提示药物相互作用信号。
- 这些信号需在针对特定联用组合的稳健观察性研究中进一步检验。
研究设计与样本
- 范围综述,检索英文文献,发表时间1990年1月1日至2025年11月24日。
- 纳入报告18岁及以上人群联用β受体阻滞剂与SSRI后任何不良事件的研究,不限研究设计。
- 从2211条独立记录中筛选117篇全文,最终纳入48篇文章。
- 纳入文章中8篇为综述文章,引用其他已纳入的实证研究。
- 纳入研究多数为干预性研究(n=19,36.9%)或病例报告(n=14,29.2%)。
主要发现
- 心动过缓是最常报告的不良事件(n=11),主要见于涉及美托洛尔-氟西汀、美托洛尔-帕罗西汀、美托洛尔-舍曲林或普萘洛尔-氟西汀的病例报告。
- 在探索血压变化的研究中,约半数观察到血压变化(包括低血压)。
- 神经认知相关症状表现异质,另有4篇病例报告/系列涉及自毒自杀或自伤。
临床怎么用
- 临床联用β受体阻滞剂与SSRI时应关注心动过缓与血压变化。
- 对涉及CYP2D6代谢的药物组合可提高对药代动力学相互作用的警惕。
局限性
- 纳入研究多为干预性研究与病例报告,证据类型限制因果推断。
- 多数不良事件信号来自病例报告,缺乏特定联用组合的风险 magnitude 精确估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Beta-adrenoreceptor blockers (beta-blockers) and selective serotonin reuptake inhibitors (SSRIs) are commonly used medications and often used together, such as for the treatment of anxiety. However, there is no recent review of any potential adverse events related to concomitant use of medicines from each group. This scoping review therefore aimed to provide this narrative synthesis. Key databases were searched for articles published in English from 1 January 1990 to 24 November 2025 reporting any adverse event due to the concomitant use of beta-blockers and SSRIs in people aged 18 or over. Any study design was permitted. From 2211 distinct records, 117 articles were eligible for full-text screening, and 48 articles were included. Eight of these were review articles referring to otherwise-included empirical studies. Most were interventional (n = 19, 36.9%) or case reports (n = 14, 29.2%). Bradycardia was the most frequently reported adverse event (n = 11) mostly in case reports involving metoprolol-fluoxetine, metoprolol-paroxetine, metoprolol-sertraline or propranolol-fluoxetine. Blood pressure changes (including hypotension) were observed in half of studies which explored them. Neurocognitive-related symptoms were heterogeneous and there were four case reports/series of self-poisoning suicide or self-harm. The adverse events discussed in this review could be signals for drug-drug interactions. Where mechanism was postulated, authors mostly proposed pharmacokinetically mediated effects via Cytochrome P450 2D6. Signals described in this review of potential adverse events should be examined in robust observational studies of specific beta-blocker-SSRI combinations. This will enable precise estimation of the magnitude of any associated risks and provide insight into the potential mechanism.
引用
- Cai Z, Sutton J, Archer C, et al. A scoping review of adverse events associated with concomitant beta-adrenoreceptor blockers and selective serotonin reuptake inhibitors. Br J Clin Pharmacol. 2026. PMID: 42844901. doi:10.1002/bcp.70850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。